BASSAM SINNO: Open Payments
NPI 1982767893 · ENCINITAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$506 in 22 payments from 8 companies in 2025. Trend: 2023 $390 · 2024 $506 · 2025 $506
Food & beverage: $506
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $110 |
| Alkermes, Inc. | 4 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| E.R. Squibb & Sons, L.L.C. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| ABBVIE INC. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: INGREZZA, ARISTADA, COBENFY, CAPLYTA, REXULTI, ABILIFY ASIMTUFII, INVEGA SUSTENNA, VRAYLAR.
Industry payments across CA — which companies pay providers there.
